Conference call will be held on Tuesday, March 11 at 9:00 a.m. ET
CARMEL, Ind., March 4, 2025 /PRNewswire/ — Syra Health Corp. (NASDAQ: SYRA), (“Syra Health” or the “Company”), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that it will report financial results for its fourth quarter and full year 2024 ended December 31, 2024, on Tuesday, March 11, 2025, before the market opens. The company will host a conference call that same day, March 11, 2025, at 9:00 a.m. ET, to discuss the results.
Interested parties can access the conference call via webcast, available in the investors section of the company’s website at https://ir.syrahealth.com/presentations/q4-and-full-year-2024-earnings-call.
Investors who would like to submit a question to be addressed on the call should email corbin@haydenir.com.
A webcast replay will be available in the investors section of the company’s website at https://ir.syrahealth.com/presentations/q4-and-full-year-2024-earnings-call.
About Syra Health
Syra Health is a healthcare technology company powering better health in critical areas such as behavioral and mental health, population health, and the healthcare workforce. The company’s leading-edge technology products and innovative services focus on prevention, access, and affordability. With a commitment to improving health, Syra Health is advancing healthcare solutions nationwide and around the world. For more information, please visit www.syrahealth.com.
Contacts
For Investor Inquiries:
Corbin Woodhull
Managing Director, Global Advisory
Hayden IR
602-476-1821
corbin@haydenir.com
For Media Inquiries:
Christine Drury
Director of Corporate Communications
Syra Health
463-345-5180
christined@syrahealth.com
SOURCE Syra Health
Looking for the best skin tag remover in 2025? Discover how Revitag works, plus expert…
The best probiotics for bloating and gas include strains like Lactobacillus rhamnosus GG, Lactobacillus acidophilus,…
NooCube NooCube London, May 10, 2025 (GLOBE NEWSWIRE) -- Vyvanse is a prescription medication that…
A Comprehensive Review of MEDVi’s Personalized GLP-1 Weight Loss Solutions Featuring Affordable Compounded Semaglutide and…
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology…
LOS ANGELES, May 10, 2025 (GLOBE NEWSWIRE) -- Losing weight these days can feel more…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="157px" width="400px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="12px" width="12px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="1000px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
